US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,480.06

+12.920.88%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,487.39

Open:1,467.14

Low:1,462.61

Close:1,467.14

Loading ...

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Astrazeneca's Breast Cancer Drug Recommended for Approval in EU

MT Newswires Live

AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU

Warburg Research Sticks to Its Buy Rating for Commerzbank (0RLW)

J&J: Chmp of Ema Recommended Approval of Indication Extension of Darzalex Subcutaneous Formulation in Frontline Setting

THOMSON REUTERS

1 Healthcare Stock to Own for Decades and 2 to Ignore

Ema's Chmp: Adopted Extension to Existing Indication to Extend Use of Stelara to Children With Crohn’s Disease Weighing at Least 40 Kg

THOMSON REUTERS

1 Biotech Stock to Buy in 2025, and 1 to Avoid

Pfizer Updates DEI Webpage to Focus on Merit

MT Newswires Live

UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older

With 79% ownership of the shares, Abbott Laboratories (NYSE:ABT) is heavily dominated by institutional owners

Simply Wall St.

UK health regulator approves Moderna's RSV vaccine for people aged 60 and over

BRIEF-UK's MHRA Says mRESVIA RSV Vaccine Approved To Protect Patients Aged 60 And Over

New Treatments Give Hope to Patients With One of the Deadliest Cancers -- WSJ

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4578","NBIX","BK4583","LU1571399168.USD","LU2065171311.SGD","GILD","LU0109394709.USD","LU2324357040.USD","LU0823416689.USD","BK4588","IE00BSNM7G36.USD","LU1839511570.USD","LU2087621335.USD","LU2468319806.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","BMRN","ABVC","LU0234570918.USD","BK4566","BK4139","LU2065170008.USD","IE00B3T34201.USD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","LU1430594728.SGD","LU2065171402.SGD","IE00B7SZLL34.SGD","XENE","LU1066051498.USD","BK4532","LU2065169927.USD","LU0058720904.USD","LU0889565916.HKD","LU1066053197.SGD","BK4585","BK4550"],"gpt_icon":0},{"id":"2514632088","title":"Callan JMB Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514632088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514632088?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"SPRING BRANCH, Texas, Feb.  28, 2025  (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emerge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3034770/0/en/Callan-JMB-Unveils-Innovative-Immunization-Management-Infrastructure-Lease-Program-for-Government-Agencies-and-Private-Organizations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","BNTX","BK4131","BK4551","BK4585","BK4548","BK4139","CJMB","BK4568"],"gpt_icon":0},{"id":"2514322448","title":"InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322448","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322448?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"JENA, Germany, Feb. 28, 2025  -- InflaRxN.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum  and hidradenitis suppurativa , to be presented during the 2025 American Academy of Dermatology  Annual Meeting, March 7 - 11, in Orlando, FL.Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are proud to announce that all of our submitted abstracts have been accepted for presentation at the AAD Annual Meeting, reflecting the considerable scientific work that has gone into the clinical development of vilobelimab in pyoderma gangrenosum  and hidradenitis suppurativa . In HS, we are presenting for the first time the reduction in draining tunnels  with vilobelimab, and the relevance of our modified HiSCR which weighs the importance of these dTs which have a devastating impact on patients with HS.”About Vilobelimab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-showcase-vilobelimab-role-immuno-140000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2552382058.USD","LU0096364046.USD","LU0320765646.SGD","LU2242646821.SGD","IE00BLSP4239.USD","SG9999001440.SGD","BK4535","SG9999002224.SGD","LU1585245621.USD","BK4588","LU2552382132.HKD","LU1430594728.SGD","SG9999015358.SGD","BK4551","BK4139","ARDS","LU1280957306.USD","BK4533","LU0234572021.USD","LU0323591593.USD","IE00B3T34201.USD","LU1066053197.SGD","IE00BLSP4452.SGD","IFRX","IE00B1XK9C88.USD","LU1868836757.USD","SG9999002232.USD","LU0237698245.USD","BK4585","LU2242652126.USD","BK4534","PG","BK4568","BNTX","LU0124676726.USD","LU2129689605.HKD","LU2129689431.USD","IE00BWXC8680.SGD","LU1868837300.USD","USA","SG9999015341.SGD","BK4550","LU2552382215.SGD","LU2129689514.USD","LU0234570918.USD","LU0098860793.USD","BK4018","BK4504","BK4581","LU0689626769.HKD"],"gpt_icon":0},{"id":"2514661324","title":"Astrazeneca's Breast Cancer Drug Recommended for Approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2514661324","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514661324?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:38","pubTimestamp":1740749902,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Friday its Enhertu drug has been recommended for approval in the European Union for treatment of adults with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy.Enhertu is a antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by the two companies.The Committee for Medicinal Products for Human Use of the European Medicines Agency, which gave the recommendation for approval, based its opinion on results from a phase 3 trial that evaluated the efficacy and safety of the drug, Astrazeneca said.The recommendation will be reviewed by the European Commission, which has the authority to grant marketing authorization for the drug, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","LU0320765992.SGD","LU2236285917.USD","BK4585","LU0109394709.USD","LU2417539215.USD","LU0889565916.HKD","AZN","BK4588","LU2462157665.USD","LU2456880835.USD","BK4156","BK4007","BK4568"],"gpt_icon":0},{"id":"2514321468","title":"AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321468","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321468?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:15","pubTimestamp":1740748553,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyos-enhertu-recommended-for-approval-in-eu?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyos-enhertu-recommended-for-approval-in-eu?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4156","BK4007","LU2236285917.USD","BK4585","BK4568","BK4588","DSNKY","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU2456880835.USD","LU2462157665.USD","AZN","LU2417539215.USD"],"gpt_icon":0},{"id":"2514214553","title":"Warburg Research Sticks to Its Buy Rating for Commerzbank (0RLW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514214553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514214553?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:15","pubTimestamp":1740748532,"startTime":"0","endTime":"0","summary":"In a report released today, Andreas Plaesier from Warburg Research maintained a Buy rating on Commerzbank (0RLW – Research Report), with a price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-its-buy-rating-for-commerzbank-0rlw-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-its-buy-rating-for-commerzbank-0rlw-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","BK4551","BK4548","BK4535","BK4585","BK4139","BK4588","BK4568"],"gpt_icon":0},{"id":"2514329763","title":"J&J: Chmp of Ema Recommended Approval of Indication Extension of Darzalex Subcutaneous Formulation in Frontline Setting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329763?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:12","pubTimestamp":1740748351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0RK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0203345920.USD","LU1196500208.SGD","IE00BVYPNV92.GBP","LU1929549753.HKD","LU1718418525.SGD","IE00BGHQF631.EUR","BK4559","LU1162221912.USD","IE00BJJMRZ35.SGD","BK4568","IE00B1BXHZ80.USD","JNJ","LU2347655156.SGD","LU0345770308.USD","SG9999002224.SGD","LU0795875169.SGD","IE0034235303.USD","LU0345769128.USD","LU1674673691.USD","IE0002141913.USD","LU2129689605.HKD","IE00B19Z3581.USD","LU1061106388.HKD","LU0098860793.USD","LU2468319806.SGD","LU1244550221.USD","LU1057294990.SGD","IE00B42XCP33.USD","LU1280957306.USD","LU2129689514.USD","IE00BVYPNW00.USD","LU0234570918.USD","LU2430703095.HKD","IE0009355771.USD","BK4592","LU0345769631.USD","SG9999002232.USD","LU1732800096.USD","LU2592432038.USD","LU0203347892.USD","LU0234572021.USD","LU1023059063.AUD","IE00BDGV0183.EUR","IE00B7SZLL34.SGD","BK4007","LU1914381329.SGD","LU1894683264.USD","LU0466842654.USD","LU1935042991.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2516630313","title":"1 Healthcare Stock to Own for Decades and 2 to Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630313","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516630313?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:02","pubTimestamp":1740747753,"startTime":"0","endTime":"0","summary":"Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.3%. This drop is a stark contrast from the S&P 500’s 5.1% gain.Only some companies are subject to these dynamics, however, and a handful of high-quality businesses can deliver earnings growth in any environment. Taking that into account, here is one healthcare stock poised to generate sustainable market-beating returns and two best left ignored.Founded in 2010 and widely known for its COVID-19 vaccine, Moderna  is a biotechnology company focused on developing messenger RNA  therapeutics and vaccines.Sales tumbled by 59% annually over the last two years, showing market trends are working against its favor during this cycle. Free cash flow margin dropped by 369.1 percentage points","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/1-healthcare-stock-own-decades-130233144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ23171101.USD","LU1720051017.SGD","LU2505996509.AUD","SG9999011175.SGD","BK4533","LU1670628061.USD","LU2357305700.SGD","LU0882574055.USD","SG9999004303.SGD","BK4532","HCSG","EVH","LU2430703251.USD","BK4137","ELV","LU0234570918.USD","LU1720051108.HKD","LU0006306889.USD","BK4534","LU1057294990.SGD","LU0061474960.USD","LU2362541273.HKD","LU0208291251.USD","LU2362541513.USD","SG9999003800.SGD","AMN","BK4568","BK4167","LU0114720955.EUR","LU0957791311.USD","LU0211331839.USD","LU0433182093.SGD","LU1489326972.SGD","LU0170899867.USD","LU0878866978.SGD","LU0314106906.USD","LU0251142724.SGD","LU2592432038.USD","BK4501","LU0345770308.USD","MRNA","SG9999001077.SGD","BK4139","LU1023059063.AUD","LU2244417387.USD","LU0106261372.USD","LU0985489474.SGD","LU2505996681.GBP","LU0289739699.SGD","LU1548497426.USD"],"gpt_icon":1},{"id":"2514326980","title":"Ema's Chmp: Adopted Extension to Existing Indication to Extend Use of Stelara to Children With Crohn’s Disease Weighing at Least 40 Kg","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326980?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:45","pubTimestamp":1740746748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IE00BSNM7G36.USD","LU0466842654.USD","BK4533","IE0034235303.USD","LU2129689605.HKD","LU0640476718.USD","LU1244550494.USD","LU1732800096.USD","IE000M9KFDE8.USD","LU1066053197.SGD","LU1023059063.AUD","LU1032955483.USD","IE00BFTCPJ56.SGD","LU2129689431.USD","LU1221951046.USD","LU1280957306.USD","BK4559","LU0203345920.USD","JNJ","LU1674673691.USD","BK4532","LU1778281490.HKD","LU2112291526.USD","BK4581","LU1057294990.SGD","LU1935042991.SGD","BK4592","BK4534","LU1244550221.USD","LU1894683264.USD","LU0345769631.USD","IE00B2B36J28.USD","IE00B42XCP33.USD","IE00B19Z3581.USD","LU0345770993.USD","BK4568","LU0795875169.SGD","LU1894683348.USD","LU2505996509.AUD","LU2430703095.HKD","IE00BJJMRZ35.SGD","IE00BVYPNV92.GBP","LU1914381329.SGD","LU2347655156.SGD","LU0234570918.USD","LU1066051498.USD","LU0889566641.SGD","BK4588","LU1196500208.SGD"],"gpt_icon":0},{"id":"2514032941","title":"1 Biotech Stock to Buy in 2025, and 1 to Avoid","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032941","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032941?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"Viking Therapeutics is developing promising therapies in a popular and rapidly growing therapeutic area.Novavax failed to gain traction in the COVID-19 market, and doesn't have hugely promising candidates.Viking Therapeutics  and Novavax  were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/28/1-biotech-stock-to-buy-in-2025-and-1-to-avoid/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4547","BK4588","NVAX","BK4585","BK4139","BK4568"],"gpt_icon":0},{"id":"2514328449","title":"Pfizer Updates DEI Webpage to Focus on Merit","url":"https://stock-news.laohu8.com/highlight/detail?id=2514328449","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514328449?lang=en_us&edition=fundamental","pubTime":"2025-02-28 19:49","pubTimestamp":1740743395,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) revised its diversity, equity, and inclusion webpage Thursday to focus on merit, reflecting broader adjustments by companies in response to the Trump administration's rollback of DEI poli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BBT3K403.USD","BK4007","BK4550","BK4585","SG9999013999.USD","IE00B19Z3581.USD","LU1894683348.USD","LU0225284248.USD","IE00BLSP4452.SGD","BK4533","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","LU1883839398.USD","SG9999003800.SGD","SG9999011175.SGD","LU0122379950.USD","LU0456855351.SGD","LU1894683264.USD","LU0868494617.USD","PFE","SG9999002224.SGD","PFE.AU","LU0234572021.USD","LU0058720904.USD","BK4194","LU0985481810.HKD","BK4534","SGXZ57979304.SGD","BK4581","BK4592","LU0225771236.USD","DEI","LU0170899867.USD","LU1066053197.SGD","BK4588","BK4599","LU1066051498.USD","SG9999001176.USD","IE0002270589.USD","LU0321505868.SGD","BK4568","LU1023059063.AUD","LU0306807586.USD","IE00B19Z3B42.SGD","BK7095","BK4223","IE00BLSP4239.USD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2514347556","title":"UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older","url":"https://stock-news.laohu8.com/highlight/detail?id=2514347556","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514347556?lang=en_us&edition=fundamental","pubTime":"2025-02-28 19:07","pubTimestamp":1740740878,"startTime":"0","endTime":"0","summary":"UPDATE 1-UK health regulator approves Moderna's RSV vaccine for adults aged 60 and olderAdds details on vaccine in paragraph 2, details on disease in paragraphs 3 & 4Feb 28  - Britain's health regulator said on Friday it has approved Moderna's MRNA.O vaccine for respiratory syncytial virus in adults 60 years and older. The shot, branded as mRESVIA, is for the prevention of lower respiratory tract disease in older adults, the Medicines and Healthcare products Regulatory Agency  said.RSV is a common virus that spreads very easily and causes infections that can be mild, with cold-like symptoms, but can also cause more serious problems, such as lung infections and pneumonia.Older adults are at risk of more serious complications that could lead to hospital admission and even death.GSK's GSK.L vaccine Arexvy and Pfizer's <PFE.N> shot Abrysvo are approved for use in individuals over the age of 60 in the UK.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1302929846.USD","LU0203345920.USD","LU1202635105.USD","LU1228905540.USD","LU1064927863.SGD","LU1883839398.USD","LU1400636574.HKD","BK4568","LU1066051498.USD","GSK.UK","LU0971552830.HKD","BK5011","SG9999001176.SGD","BK4581","LU1035777561.USD","BK4548","LU1481599808.USD","LU1015430645.USD","BK4550","LU1481600234.SGD","BK4585","LU0225771236.USD","LU1057294990.SGD","LU1645745479.HKD","BK4534","BK4532","LU0289739699.SGD","LU0985481810.HKD","IE00BWDBJ516.SGD","MRNA","BK4592","IE00BBT3K403.USD","LU1228905037.USD","LU1400636491.USD","IE0034235071.USD","SG9999002232.USD","IE00BLSP4452.SGD","LU0203347892.USD","LU0234572021.USD","LU0545562505.USD","LU0306806265.USD","BK4588","BK4007","BK4139","SG9999001176.USD","LU1894683264.USD","BK4599","IE0002270589.USD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2514893328","title":"With 79% ownership of the shares, Abbott Laboratories (NYSE:ABT) is heavily dominated by institutional owners","url":"https://stock-news.laohu8.com/highlight/detail?id=2514893328","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514893328?lang=en_us&edition=fundamental","pubTime":"2025-02-28 19:01","pubTimestamp":1740740463,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their trading actions. A total of 25 investors have a majority stake in the company with 49% ownership. Every investor in Abbott Laboratories  should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 79% ownership. That is, the group stands to benefit the most if the stock rises .Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of Abbott Laboratories.Check out our latest analysis for Abbott Laboratories. The definition of an insider can differ slightly between different countries, but members of the board of dire","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/79-ownership-shares-abbott-laboratories-110103435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU1691799644.USD","BK4533","ABT","BK4566","LU2112291526.USD","SG9999002232.USD","LU1989763690.USD","LU0234572021.USD","LU1023059063.AUD","NYSE","BK4585","LU1914381329.SGD","BK4568","LU2089984988.USD","LU2468319806.SGD","IE0002141913.USD","LU0122379950.USD","IE00B2B36J28.USD","BK4504","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4082","LU1721429741.USD","LU1057294990.SGD","LU1721429402.USD","SG9999004303.SGD","LU2237957902.USD","IE00B4R5TH58.HKD","LU0170899867.USD","LU1989763427.SGD","LU0868494617.USD","LU2237957811.SGD","BK4592","SG9999002224.SGD","LU0266013472.USD","LU2133065610.SGD","LU1061106388.HKD","BK4581","IE00BJT1NW94.SGD","BK4588"],"gpt_icon":1},{"id":"2514027344","title":"UK health regulator approves Moderna's RSV vaccine for people aged 60 and over","url":"https://stock-news.laohu8.com/highlight/detail?id=2514027344","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514027344?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:48","pubTimestamp":1740739699,"startTime":"0","endTime":"0","summary":"UK health regulator approves Moderna's RSV vaccine for people aged 60 and overFeb 28  - Britain's health regulator said on Friday it has approved Moderna's MRNA.O vaccine to protect patients aged 60 and over against lower respiratory tract disease caused by the respiratory syncytial virus .  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","BK4534","BK4533","BK4551","BK4532","BK4588","BK4501","BK4548","MRNA"],"gpt_icon":0},{"id":"2514901344","title":"BRIEF-UK's MHRA Says mRESVIA RSV Vaccine Approved To Protect Patients Aged 60 And Over","url":"https://stock-news.laohu8.com/highlight/detail?id=2514901344","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514901344?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:37","pubTimestamp":1740739049,"startTime":"0","endTime":"0","summary":"BRIEF-UK's MHRA Says mRESVIA RSV Vaccine Approved To Protect Patients Aged 60 And OverFeb 28  - MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY: UK'S MHRA SAYS MRESVIA RSV VACCINE APPROVED TO PROTECT PATIENTS AGED 60 AND OVERUK'S MHRA SAYS MRNA RSV VACCINE TO PROTECT PATIENTS AGED 60 AND OVER AGAINST LOWER RESPIRATORY TRACT DISEASE CAUSED BY RSVSource text: [ID:]Further company coverage: MRNA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4533","BK4588","BK4548","BK4585","BK4501","BK4532","BK4534","MRNA","BK4568"],"gpt_icon":1},{"id":"2514344899","title":"New Treatments Give Hope to Patients With One of the Deadliest Cancers -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2514344899","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514344899?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:30","pubTimestamp":1740738600,"startTime":"0","endTime":"0","summary":"By Brianna Abbott | Photographs by Helynn Ospina for WSJ. Pranathi Perati was running out of time to treat her stage-four pancreatic cancer when she found out she would get another shot: a clinical trial testing a new experimental drug.Perati's odds were slim -- only 3% of late-stage pancreatic cancer patients are still alive after five years. And half of all pancreatic cancer patients live for less than a year after their diagnosis. For Perati, the drug, daraxonrasib from Revolution Medicines, has helped keep her alive for 17 months and counting.Pancreatic cancer is one of the toughest cancers to treat. Often caught late, it kills nearly 52,000 people in the U.S. each year, making it the country's third leading cause of cancer death, behind lung and colorectal. Case rates have gradually increased, particularly among younger women, in part because of rising obesity rates.Researchers believe that could change with newer therapies, particularly those that target KRAS. The gene acts as a ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0456855351.SGD","BK4007","BK4533","LU0985481810.HKD","LU1894683348.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0225771236.USD","PFE","IE0002270589.USD","LU0170899867.USD","LU0321505439.SGD","LU1883839398.USD","BK4599","SG9999003800.SGD","LU0289739699.SGD","LU1066051498.USD","LU0058720904.USD","LU1023059063.AUD","BK4581","SG9999001176.SGD","LU1066053197.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0234572021.USD","BK4534","SG9999001176.USD","LU0306806265.USD","SG9999002232.USD","BK4211","LU0225284248.USD","LU0306807586.USD","LU0868494617.USD","LU0122379950.USD","SG9999013999.USD","HOPE","SG9999002224.SGD","LU0321505868.SGD","BK4568","BK4585","BK4588","LU1894683264.USD","IE00BLSP4239.USD","IE000M9KFDE8.USD","BK4592"],"gpt_icon":0}],"pageSize":16,"totalPage":20,"pageCount":12,"totalSize":308}]}}